Zacks Research Has Negative Estimate for Perrigo Q1 Earnings

Perrigo Company plc (NYSE:PRGO) – Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for Perrigo in a report issued on Thursday, March 19th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.57 per share for the quarter, down from their prior estimate of $0.78. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.55 EPS, Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $2.18 EPS, Q1 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.63 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $2.53 EPS.

PRGO has been the topic of a number of other research reports. JPMorgan Chase & Co. dropped their target price on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Argus raised shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. Canaccord Genuity Group decreased their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $19.33.

Perrigo Stock Up 3.5%

Shares of PRGO stock opened at $9.58 on Monday. Perrigo has a 12 month low of $9.23 and a 12 month high of $28.43. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. The firm has a market cap of $1.32 billion, a PE ratio of -0.93, a price-to-earnings-growth ratio of 1.09 and a beta of 0.41. The stock has a 50 day moving average of $13.18 and a 200-day moving average of $15.91.

Perrigo (NYSE:PRGO) last announced its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. Perrigo’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 12.1%. The ex-dividend date is Monday, March 2nd. Perrigo’s payout ratio is -11.28%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRGO. Amundi grew its stake in shares of Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares during the period. Slocum Gordon & Co LLP boosted its stake in Perrigo by 1.1% in the 3rd quarter. Slocum Gordon & Co LLP now owns 53,253 shares of the company’s stock valued at $1,186,000 after buying an additional 602 shares in the last quarter. Kestra Investment Management LLC grew its position in Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after acquiring an additional 642 shares during the period. State of Wyoming raised its stake in Perrigo by 7.8% during the third quarter. State of Wyoming now owns 8,988 shares of the company’s stock worth $200,000 after acquiring an additional 653 shares in the last quarter. Finally, First Citizens Bank & Trust Co. lifted its holdings in shares of Perrigo by 4.7% during the third quarter. First Citizens Bank & Trust Co. now owns 17,323 shares of the company’s stock valued at $386,000 after acquiring an additional 775 shares during the period. Institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.